
Dr. O'Neill serves as a member of the Executive Board and provides consulting on many aspects of vision science with a specific focus on study design and regulatory requirement considerations for IND submission. Dr. O'Neill is an Assistant Adjunct Professor in the Pharmacology and Toxicology Graduate Group at University of California-Davis. He has contributed to 26 regulatory submissions in the US, EU, Australia and Japan, coauthored over 40 peer-reviewed publications, and been a Diplomate of the American Board of Toxicology since 1995. With 14 years of biotechnology and pharmaceutical development experience, Dr. O'Neill has led non-clinical development efforts regarding anti-angiogenic molecules including the targeted oncology monoclonal antibody AvastinTM, and the intra-vitreally delivered monoclonal antibody fragment LucentisTM, a treatment for the neovascular form of age-related macular degeneration.